LLY

1,048.36

+1.39%↑

JNJ

244.28

+0.03%↑

ABBV

234.47

+4.3%↑

NVS

163.08

+1.41%↑

MRK

122.45

+0.88%↑

LLY

1,048.36

+1.39%↑

JNJ

244.28

+0.03%↑

ABBV

234.47

+4.3%↑

NVS

163.08

+1.41%↑

MRK

122.45

+0.88%↑

LLY

1,048.36

+1.39%↑

JNJ

244.28

+0.03%↑

ABBV

234.47

+4.3%↑

NVS

163.08

+1.41%↑

MRK

122.45

+0.88%↑

LLY

1,048.36

+1.39%↑

JNJ

244.28

+0.03%↑

ABBV

234.47

+4.3%↑

NVS

163.08

+1.41%↑

MRK

122.45

+0.88%↑

LLY

1,048.36

+1.39%↑

JNJ

244.28

+0.03%↑

ABBV

234.47

+4.3%↑

NVS

163.08

+1.41%↑

MRK

122.45

+0.88%↑

Strona główna・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Open

1.14 1.79

Buy Sell

Overview

Share price change

24h

Current

Min

1.11

Max

1.15

Key metrics
By Trading Economics
Income	17M -26M
Employees	171
EBITDA	19M -23M

Dividends
By Dow Jones
Next Earnings	26 lut 2026

Market Stats
By TradingEconomics
Market Cap	-31M 72M
Previous open	-0.65
Previous close	1.14

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 lut 2026, 23:57 UTC

Hot Stocks

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12 lut 2026, 23:35 UTC

Earnings

Major Market Movers

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12 lut 2026, 23:28 UTC

Earnings

Applied Materials Profit Rises on Soaring AI Demand -- Update

12 lut 2026, 21:47 UTC

Earnings

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13 lut 2026, 00:00 UTC

Market Talk

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12 lut 2026, 23:47 UTC

Market Talk

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12 lut 2026, 23:38 UTC

Market Talk

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12 lut 2026, 23:33 UTC

Earnings

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12 lut 2026, 23:09 UTC

Market Talk

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12 lut 2026, 22:55 UTC

Earnings

Hot Stocks

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12 lut 2026, 22:46 UTC

Market Talk

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12 lut 2026, 22:23 UTC

Earnings

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12 lut 2026, 22:15 UTC

Earnings

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12 lut 2026, 22:15 UTC

Earnings

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12 lut 2026, 22:15 UTC

Earnings

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12 lut 2026, 22:15 UTC

Earnings

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12 lut 2026, 22:00 UTC

Earnings

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 lut 2026, 22:00 UTC

Earnings

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12 lut 2026, 22:00 UTC

Earnings

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12 lut 2026, 22:00 UTC

Earnings

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12 lut 2026, 22:00 UTC

Earnings

12 lut 2026, 22:00 UTC

Earnings

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12 lut 2026, 21:57 UTC

Earnings

XP 4Q Rev BRL4.95B >XP

12 lut 2026, 21:52 UTC

Earnings

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 lut 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

12 lut 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 lut 2026, 21:47 UTC

Earnings

Morningstar 4Q Rev $641M >MORN

12 lut 2026, 21:39 UTC

Earnings

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 lut 2026, 21:38 UTC

Earnings

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Rating Consensus

By TipRanks

Sell

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.